Compare Quest Diagnostics Inc (DGX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs TORM plc — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while TORM plc trades at $29.68 (market cap $3.02B). The key difference: Quest Diagnostics Inc is far larger — about 7.5× TORM plc's market cap, and TORM plc pays the higher dividend (9.52%). Which is the better fit depends on your goals.
| DGX | TRMD | |
|---|---|---|
Market Cap | $22.80B | $3.02B |
Sector | Health | Technology |
52-Week High | $216.02 | $34.87 |
52-Week Low | $166.42 | $17.46 |
Enterprise Value | $28.82B | $3.90B |
Dividend Yield | 1.67% | 9.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
TRMD trades at $28.86, down 2.1% today, with a bullish technical signal supported by moving averages despite neutral oscillators. The company shows strong fundamentals with a P/E of 8.62, net income margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, highlighting strong freight market conditions and operational execution.
Outlook remains positive with 100% analyst buy ratings and attractive valuation metrics. Key opportunities include the upcoming Q2 2026 earnings report and consistent dividend payments. Risks include earnings volatility, geopolitical impacts on shipping rates, and competitive pressures in the tanker market that could affect future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
